Compare Natera Inc. Common Stock (NTRA) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs United States Oil ETF — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while United States Oil ETF trades at $152.87 (market cap $1.86B). The key difference: Natera Inc. Common Stock is far larger — about 30.7× United States Oil ETF's market cap, and United States Oil ETF is more actively traded (2,900,350 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and United States Oil ETF for 21 Days on average.
| NTRA | USO | |
|---|---|---|
Market Cap | $57.03B | $1.86B |
Volume | 1,131,157 | 2,900,350 |
Sector | Health | — |
52-Week High | $425.64 | $161.86 |
52-Week Low | $179.42 | $66.17 |
Typical Hold Time | 0 Days | 21 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
USO is trading at $153.09, up 1.36% with a bullish technical outlook supported by strong moving average signals. Recent news highlights ongoing Middle East tensions affecting oil supply chains, with OPEC+ maintaining steady output targets while G-7 nations plan strategic fuel releases to curb prices. The stock shows positive momentum despite mixed oscillators and geopolitical uncertainties.
The outlook remains cautiously optimistic with technical strength offset by fundamental data gaps and geopolitical risks. Investment opportunity exists if supply disruptions persist, but volatility from political events and coordinated government interventions pose significant near-term risks for energy sector investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
